Skip to main content
OpenTrials
Completed

NCT Number: NCT01733017

Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure

The purpose of is to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Kentucky, College of Nursing, Lexington, Kentucky, United States

Loading trial locations.

About this study

For a majority of patients with advanced heart failure, medical treatment is only partially effective in relieving heart failure symptoms. Therefore, it is recommended that palliative care be initiated soon after diagnosis. There is a need for complementary, nonpharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Clinical trials to date have only tested each nutrient individually. There is strong theoretical rationale that a combined intervention targeting all three nutrients would have substantial benefit in relieving symptoms in advanced heart failure. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this placebo controlled study are 1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; 2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and 3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 150 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group (75 per group). The nutrition intervention group will receive a theory based education and skill building intervention designed to decrease dietary sodium intake to ~2 g per day. A research nurse will make 4 home visits and one follow-up telephone call over 6 months to provide the education-skill building intervention. The intervention group will take 3 omega-3 fatty acid capsules (350 mg eicosapentaenoic acid and 50 mg docosahexaenoic acid) and consume tomato juice or other tomato-based products containing 20-25 mg of lycopene daily for six months. The placebo group will receive the same number of visits and phone calls but only general nutrition information will be provided. They will take 3 placebo capsules containing rice oil (500 mg/capsule) and consume their choice of fruit juices that do not contain lycopene daily for six months. Data will be collected in person at baseline, 3 months, and 6 months by a research assistant blinded to the group assignment. Patients will be followed for an additional 6 months by telephone to collect longer term data on symptom burden and quality of life as well as heart failure hospitalization and all-cause mortality at 9 and 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • chronic heart failure with either preserved or non-preserved ejection fraction
  • for chronic heart failure, have undergone evaluation of heart failure and optimization of medical therapy, for patients discharged from hospital for acute/newly diagnosed heart failure, have undergone evaluation of heart failure and optimization of medical therapy for at least 1 month post discharge
  • New York Heart Association functional classification of II, III or IV
  • have not been referred for heart transplantation
  • able to read and speak English
  • no cognitive impairment that precludes giving informed consent or ability to follow protocol instruction.

Exclusion criteria

  • BMI < 17 kg/m2 or > 46 kg/m2
  • co-existing illness documented in the medical record known to be associated with systemic inflammation decreased appetite or absorption, fatigue, edema, or weight loss
  • currently taking dietary supplements that contain lycopene or omega-3 fatty acids
  • allergy to rice bran oil

Treatment and study plan

Sodium reduction

Behavioral

Teaching and skill building to reduce dietary sodium

omega 3 and lycopene supplements

Dietary Supplement

omega-3 fatty acid supplements and juices containing lycopene

rice bran oil capsules

Dietary Supplement

placebo capsules

Other names: placebo

Generic dietary feedback from

Behavioral

Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months

Other names: attention control

Primary outcomes

  1. Event-Free Survival

    Time frame: 12 months

    Combined endpoint of cardiac-related hospitalization and all cause mortality

  2. Symptom burden

    Time frame: baseline, 3, 6, 9, and 12 months

    combined score of symptom severity, frequency, and distress for common symptoms of heart failure

  3. Quality of life

    Time frame: baseline, 3, 6, 9, 12 months

    heart failure related quality of life

Secondary outcomes

  1. omega-3 index

    Time frame: baseline, 3, 6, 9, 12 months

    the ratio of EPA plus DHA as a percentage of total fatty acids in the cell membrane of erythrocytes

  2. oxidative stress

    Time frame: baseline, 3, 6, 9, 12 months

    serum levels of malondialdehyde and 8-iso-PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen free radical production exceeding antioxidant capacity

  3. Inflammation

    Time frame: baseline, 3, 6, 9, 12 months

    Serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors: sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity; interleukin-10 (IL-10) will be measured as a marker of anti-inflammatory cytokine activity

  4. Lycopene

    Time frame: baseline, 3, 6, 9, 12 months

    Plasma lycopene will be measured as a marker intervention effectiveness

  5. Sodium intake

    Time frame: baseline, 3, 6, 9, 12 months

    Three 24-hour diet recall interviews at each timepoint will be used estimate sodium intake and to identify high sodium foods and eating patterns for the sodium reduction component of the intervention.

Sponsors and collaborators

Lead sponsor

Terry Lennie

Other

Collaborators

  • Ohio State University

Registry information

Official study title

Nutrition Intervention to Reduce Symptoms in Patients With Advanced Heart Failure

Acronym: NIHFT

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Nov 26, 2012
Registry last updated
Mar 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.